

Sample Billing and Coding

for ACTEMRA® (tocilizumab) and Rituxan® (rituximab)

Considerations for claims submission



ACTEMRA Indication

ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

BOXED WARNING

RISK OF SERIOUS INFECTIONS:

Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled.

Reported infections include:

- Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent tuberculosis before ACTEMRA use and during therapy. Treatment for latent infection should be initiated prior to ACTEMRA use.
- Invasive fungal infections, including candidiasis, aspergillosis, and pneumocystis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.
- Bacterial, viral and other infections due to opportunistic pathogens.

The risks and benefits of treatment with ACTEMRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ACTEMRA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

Rituxan Indication

Rituxan[®] (rituximab), in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more TNF antagonist therapies.

BOXED WARNINGS

- <u>Infusion-Related Reactions</u>: Rituxan administration can result in serious, including fatal infusion-related reactions. Deaths within 24 hours of Rituxan infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Monitor patients closely. Discontinue Rituxan infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion-related reactions.
- <u>Severe Mucocutaneous Reactions</u>: Severe, including fatal, mucocutaneous reactions can occur in patients receiving Rituxan.
- <u>Hepatitis B Virus (HBV) Reactivation</u>: HBV reactivation can occur in patients treated with Rituxan, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with Rituxan. Discontinue Rituxan and concomitant medications in the event of HBV reactivation.
- <u>Progressive Multifocal Leukoencephalopathy (PML)</u>, including fatal PML, can occur in patients receiving Rituxan.



Sample Coding for ACTEMRA for Adults With RA: IV Infusion and SC Injection

This coding information may assist you as you complete the payer forms for ACTEMRA

ТҮРЕ	CODE	DESCRIPTION	
	M05.00-M05.09	Felty's syndrome (rheumatoid arthritis with splenoadenomegaly and leukopenia)	
	M05.10-M05.19	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	
	M05.20-M05.29	Rheumatoid vasculitis with rheumatoid arthritis	
	M05.30-M05.39	Rheumatoid heart disease with rheumatoid arthritis	
	M05.40-M05.49	Rheumatoid myopathy with rheumatoid arthritis	
	M05.50-M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis	
	M05.60-M05.69	Rheumatoid arthritis with involvement of other organs and systems	
Diagnosis: ICD-10-CM	M05.70-M05.79	Rheumatoid arthritis with rheumatoid factor without organ or systems involvement	
	M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	
	M05.80-M05.8A	Other rheumatoid arthritis with rheumatoid factor	
	M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	
	M06.00-M06.09	Rheumatoid arthritis without rheumatoid factor	
	M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	
	M06.80-M06.8A	Other specified rheumatoid arthritis	
	M06.9	Rheumatoid arthritis, unspecified	
Drug: HCPCS	J3262	Injection, tocilizumab, 1 mg	
HCPCS: Modifier* Note: Beginning July 1, 2023, CMS requires	JW	Drug amount discarded/not administered to any patient	
the use of the JZ modifier to indicate there were no units of a drug discarded.	JZ	Zero drug amount discarded/not administered to any patient	

TYPE	CODE		DESCRIPTION	
	10-digit	11-digit		
	50242-135-01	50242-135-01 50242-0135-01 80 mg (4 mL) single-use vial		
Drug: NDC Note: Payer requirements	50242-136-01 50242-0136-01 200 mg (10 mL) single-use vial		200 mg (10 mL) single-use vial	
regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for	50242-137-01	50242-137-01 50242-0137-01 400 mg (20 mL) single-use vial		
your reference.	50242-138-01	50242-0138-01	Prefilled syringe providing 162 mg per 0.9 mL	
	50242-143-01	50242-0143-01	162 mg per 0.9 mL autoinjector (ACTPen®)	
	96.	365	Intravenous infusion, for therapy, prophylaxis or diagnosis (specify substance or drug); initial, up to 1 hour	
Administration procedures: CPT	96	413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	
	96	372	Therapeutic, prophylactic or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	

CMS=Centers for Medicare & Medicaid Services; CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; IV=intravenous; NDC=National Drug Code; RA=rheumatoid arthritis; SC=subcutaneous.

*The JW modifier will be required on claims for all single-dose containers or single-use drugs when an amount is discarded. The JZ modifier is required on claims for all single-dose containers or single-use drugs when no drug is discarded/administered to any patient as of July 1, 2023. For more information on the JZ modifier, visit CMS.gov.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any item or service. Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

When submitting claims, be sure to:



Communicate with appropriate payer contacts to determine plan-specific requirements

• Monitor the first few claims submitted to each plan to learn about the plan's requirements so you can apply the knowledge to future claims

• Keep complete, legible and easily accessible records



Sample Coding for Rituxan for Adults With RA

ТҮРЕ	CODE		DESCRIPTION	T	ТҮРЕ		CODE	
	M05.00-N	105.09	Felty's syndrome (rheumatoid arthritis with splenoadenomegaly and leukopenia)		HCPCS: Modifier* Note: Beginning July 1, 2023, CMS requires the use of the JZ modifier to indicate there were no units of a drug discarded.		WL	
	M05.10-N	105.19	Rheumatoid lung disease with rheumatoid arthritis	the use of the JZ mod				
	M05.20-N	105.29	Rheumatoid vasculitis with rheumatoid arthritis	were no units of a dru	ig discarded.	JZ		
	M05.30-N	105.39	Rheumatoid heart disease with rheumatoid arthritis	B NDO		10-digit		
	M05.40-N	105.49	Rheumatoid myopathy with rheumatoid arthritis		Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference.		5024	
	M05.50-N	105.59	Rheumatoid polyneuropathy with rheumatoid arthritis				500	
	M05.60-N	105.69	Rheumatoid arthritis with involvement of other organs and systems			50242-053-06	502	
Diagnosis: ICD-10-CM	M05.70-N	105.79	Rheumatoid arthritis with rheumatoid factor without organ or systems involvement				Cher up to	
	M05.7	7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement				Cher	
	M05.80-N	105.8A	Other rheumatoid arthritis with rheumatoid factor				addit prima	
	M05.	9	Rheumatoid arthritis with rheumatoid factor, unspecified			ADMINI		
	M06.00-N	106.09	Rheumatoid arthritis without rheumatoid factor			ADMIN		
	M06.0A		Rheumatoid arthritis without rheumatoid factor, other specified site		Administration procedures: CPT		Intra (spec	
	M06.80-M06.8A		Other specified rheumatoid arthritis	procedures: C			hour 9636	
	M06.9 J9312		Rheumatoid arthritis, unspecified					
			Injection, rituximab, 10 mg				admi sequ	
	Other drugs: for ancillary premedications and supplies as appropriate	J1100	Injection, dexamethasone sodium phosphate, 1 mg			dru dru 96375 96	Ther	
Drug: HCPCS		J1200	Injection, diphenhydramine HCL, up to 50 mg				drug drug	
		J2920	Injection, methylprednisolone sodium succinate, up to 40 mg				9637 9637	
		J2930	Injection, methylprednisolone sodium succinate, up to 125 mg				as a s admi	
		J7030	Infusion, normal saline solution, 1000 cc Infusion, normal saline solution, sterile (500 mL = 1 unit) *The JW modifier will be required on claims for a for all single-dose containers or single-use drug modifier with OMC and the second seco					
		J7040						
		J7050 Infusion, normal saline solution, 250 cc modifier, visit CMS.gov. Linfusion, normal saline solution, 250 cc submitting the claim for the item or service. Plea						

y patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech and Biogen do not make any representation or guarantee concerning reimbursement or coverage for any item or service.

CC	DE	DESCRIPTION			
J	W	Drug amount discarded/not administered to any patient			
	IZ	Zero drug amount discarded/not administered to any patient			
11-digit					
-21	50242-0051-21	100 mg/10 mL single-dose vial			
-06	50242-0053-06	500 mg/50 mL single-dose vial			

ADMINISTRATION CODES FOR RITUXAN

Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug

Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)

ADMINISTRATION CODES FOR SUPPORTIVE MEDICINES

Intravenous infusion, for therapy, prophylaxis or diagnosis (specify substance or drug); additional sequential infusion, up to 1 hour (List separately in addition to code for primary procedure) (Report 96367 in conjunction with 96365, 96374, 96409, 96413 if provided as a secondary or subsequent service after a different initial service is administered through the same IV access. Report 96367 only once per sequential infusion of same infusate mix)

Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/ drug (List separately in addition to code for primary procedure) (Use 96375 in conjunction with 96365, 96374, 96409, 96413) (Report 96375 to identify intravenous push of a new substance/drug if provided as a secondary or subsequent service after a different initial service is administered through the same IV access)

tainers or single-use drugs when an amount is discarded. The JZ modifier is required on claims discarded/administered to any patient as of July 1, 2023. For more information on the JZ



CMS-1500 Example Claim Form

The CMS-1500 claim form is used by some payers to bill for services provided in the **noninstitutional** (physician office) setting.

CMS-1450/UB-04 Example Claim Form

44

CREATION DATE

NUBC halord Unitern LIC9213257

The CMS-1450 /UB-04 claim form is used by some payers to bill for services provided in the **institutional** (hospital) setting.

3a PAT. CNTL # b. MED. REC. #

HEALTH INSURANCE CLAIM FORM APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02		R. R			
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/					8 PATIENT NAME a
	12				b
1. MEDICARE MEDICAID TRICARE CHAN		PICA PICA			10 BIRTHDATE 11 SEX 12 DATE AL
(Medicare#) (Medicaid#) (ID#/DoD#) (Memb 2. PATIENT'S NAME (Last Name, First Name, Middle Initial)	er ID#) (ID#) (ID#) (ID#) (ID#) (ID#)	4. INSURED'S NAME (Last Name, First Name, Middle Initial)		Input diagnosis	31 OCCURRENCE 32 OCCURRENCE CODE DATE CODE DATE
	M F		21	code(s) here	
5. PATIENT'S ADDRESS (No., Street)	6. PATIENT RELATIONSHIP TO INSURED Self Spouse Child Other	7. INSURED'S ADDRESS (No., Street)			38
CITY STA			24D	Input HCPCS code,	
ZIP CODE TELEPHONE (Include Area Code)		ZIP CODE TELEPHONE (Include Area Code)	240	NDC and appropriate	
9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)	10. IS PATIENT'S CONDITION RELATED TO:	() 11. INSURED'S POLICY GROUP OR FECA NUMBER		CPT administration	42 REV. CD. 43 DESCRIPTION
				code(s) and required	42 43
a. OTHER INSURED'S POLICY OR GROUP NUMBER	a. EMPLOYMENT? (Current or Previous) YES NO	a. INSURED'S DATE OF BIRTH SEX		modifier(s) on separate lines	42 43
. RESERVED FOR NUCC USE	b. AUTO ACCIDENT? PLACE (State)	b. OTHER CLAIM ID (Designated by NUCC)		separate intes	5
D. RESERVED FOR NUCC USE	. OTHER ACCIDENT?	I I □ INSURANCE PLAN NAME OR PROGRAM NAME		Input number of units	6 7
J. INSURANCE PLAN NAME OR PROGRAM NAME	YES NO 10d. CLAIM CODES (Designated by NUCC)	d, IS THERE ANOTHER HEALTH BENEFIT PLAN?	24G	Input number of units for each line item	·
		YES NO <i>If yes</i> , complete items 9, 9a, and 9d.			*
READ BACK OF FORM BEFORE COMPLET 12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE Lauthorize	the release of any medical or other information necessary	13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE I authorize payment of medical benefits to the undersigned physician or supplier for			n
to process this claim. I also request payment of government benefits eit below.	ner to myself or to the party who accepts assignment	services described below.			10 10
SIGNED	DATE 15. OTHER DATE	SIGNED Y			2
QUAL.	QUAL. MM DD YY	FROM TO			56
17. NAME OF REFERRING PROVIDER OR OTHER SOURCE	17a. 17b. NPI	18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES MM DD YY MM DD YY FROM TO TO			17 10
19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)		20. OUTSIDE LAB? \$ CHARGES			
DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to s	ervice line below (24E) ICD Ind.	22. RESUBMISSION ORIGINAL REF. NO.			20
1 в с	D	23. PRIOR AUTHORIZATION NUMBER			22 23 PAGE OF
I J K	. <u> </u>				20 PAGE OF 50 PAYER NAME
24. A. DATE(S) OF SERVICE B. C. D. PRO From To PLACE OF (E MM DD YY MM DD YY SERVICE EMG CPT/F	CEDURES, SERVICES, OR SUPPLIES xplain Unusual Circumstances) ICPCS MODIFIER POINTER	S F. G. H. J. J. DAYS ERST ID. RENDERING S CHARGES UNITS Find QUAL. PROVIDER ID. #			^
	24D				c
	240				S8 INSURED'S NAME
		NPI 🔛			•
					6 63 TREATMENT AUTHORIZATION CODES
		NPI			1
		NA N			a
					66
25. FEDERAL TAX I.D. NUMBER SSN EIN 26. PATIENT	S ACCOUNT NO. 27. ACCEPT, ASSIGNMENT?	28. TOTAL CHARGE 29. AMOUNT PAID 30. Rsvd for NUCC Use			69 AD TO PATIENT
	YES NO	\$ \$ S ANDOR FAID SU INVECTOR			74 PRINCIPAL PROCEDURE CODE DATE 0
INCLUDING DEGREES OR CREDENTIALS	FACILITY LOCATION INFORMATION	33. BILLING PROVIDER INFO & PH # ()			c. OTHER PROCEDURE DATE d.
(I certify that the statements on the reverse apply to this bill and are made a part thereof.)					80 REMARKS

				_			
				4 Tr OF	OILL		
(NO.	6 STAT	EMENT CO	VERS PERIOD THROUGH	7			
	с	d		0			
25 26	27		CDT 30 NTE				
DUGH 36 CODE	OCC FR	URRENCE S	PAN THROUGH	37		12	Input revenue code
						42	input revenue coue
40 CODE	VALUE COO AMOUN	DES IT	41 CODE	VALUE CODES AMOUNT		43	Input NDC
						43	inputiteo
							Input HCPCS code
RV. UNITS	47 TOTAL CH	ARGES	48 NON-CO	WERED CHARGES	49	44	on one line and
					1		appropriate CPT
46					3		administration
<u> </u>					4		code(s) and required
					•		modifier(s) on a
					7		separate line
					•		
					10	46	Number of units for
					12	40	each line item
					13		
					15	66	Input diagnosis
					17		code(s) here
					18		
					20		
					21		
TALS 📥		-			23		
5 EST. AMOUNT I	DUE :	56 NPI 57			_		
		OTHER			•		
AME		PRV ID 62 INSUR	NCE GROUP N	D.	C		
					^		
					e c		
65 EV	IPLOYER NAM	IE.					
_	0			68	c		
	<u>G</u> P		Q				
IDING NPI	b		C 73 QUAL				
			FIRST				
ATING NPI			QUAL				
R NPI			QUAL				
R NPI			FIRST				
			FIRST				
IFICATIONS ON T	HE REVERSE	APPLY TO 1	THIS BILL AND A	RE MADE A PART I	HEREOF		



Your Direct Connection to Genentech

To learn more about our programs and services:



Get support from your Genentech representative Call our **Specialists** at (**866**) **681-3261** Monday through Friday, 6 a.m. to 5 p.m. PT

BOXED WARNING and Additional Important Safety Information (cont)

or Genentech-Access.com/Rituxan-RA

ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA.

Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations. Use ACTEMRA with caution in patients who may be at risk for GI perforations.

Monitor patients for signs and symptoms of hepatic injury. Modify or discontinue ACTEMRA if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop.

Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests.

Hypersensitivity reactions, including anaphylaxis and death, have occurred.

• If anaphylaxis or other hypersensitivity reaction occurs, stop administration of ACTEMRA immediately and discontinue ACTEMRA permanently.

Avoid use of live vaccines concurrently with ACTEMRA, as clinical safety has not been established.

Other potential risks of ACTEMRA include demyelinating disorders and malignancies. Treatment with ACTEMRA is not recommended in patients with active hepatic disease or hepatic impairment.

Most common adverse reactions (\geq 5%) include upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, injection site reactions (SC only).

You may report side effects to the FDA at (800) FDA-1088 or <u>www.fda.gov/medwatch</u>. You may also report side effects to Genentech at (888) 835-2555.

Please see additional Important Safety Information in accompanying full Prescribing Information, including **BOXED WARNING**.

BOXED WARNINGS and Additional Important Safety Information (cont)

Rituxan administration can also result in additional serious, including fatal, adverse reactions including:

- Tumor lysis syndrome (TLS): Administer aggressive intravenous hydration, anti-hyperuricemic agents, monitor renal function
- Infections: Withhold Rituxan and institute appropriate anti-infective therapy. Rituxan is not recommended for use in patients with severe, active infections
- Cardiovascular adverse reactions: Discontinue infusions in case of serious or life-threatening events
- Renal toxicity: Discontinue in patients with rising serum creatinine or oliguria
- Bowel obstruction and perforation: Consider and evaluate for abdominal pain, vomiting, or related symptoms
- Immunizations: Live virus vaccinations prior to or during Rituxan treatment are not recommended
- Embryo-Fetal toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and use of effective contraception
- Patients with RA should be closely observed for signs of infection if biologic agents and/or DMARDs other than methotrexate are used concomitantly
- The use of Rituxan in patients with RA who have not had prior inadequate response to one or more TNF antagonists is not recommended
- Most common adverse reactions in patients with RA were upper respiratory tract infection, nasopharyngitis, urinary tract infection, and bronchitis. Other important adverse reactions include infusion-related reactions, serious infections, and cardiovascular events

For additional Important Safety Information, please see the Rituxan full Prescribing Information, including **BOXED WARNINGS**. *Attention Healthcare Provider: Provide Medication Guide to patient prior to Rituxan infusion.*

ACTEMRA® and its logo are registered trademarks of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group.

Rituxan® and its logo are registered trademarks of Biogen.

My Patient Solutions® is a registered trademark of Genentech, Inc.





